Quiet ASX debut for BioPharmica
Monday, 09 August, 2004
BioPharmica (ASX: BPH) made its debut on the ASX on Friday afternoon, closing slightly lower than its opening price of AUD$0.25 at $0.21.
The Perth-based company's IPO closed oversubscribed after raising $2.6 million at $0.20 per share in a spin-out from investment company Grandbridge (ASX: GBA), which stands to turn a $1 million profit from the listing.
BioPharmica is developing diagnostic and therapeutic applications for a tumour suppressor gene, HLS5, with a potential role in breast, prostate and colorectal cancers, based on research conducted at the Western Australian Institute of Medical Research.
A second project involves development of genetics-based diagnostic systems for bacterial infections, with an initial focus on diagnosing respiratory tract infections in partnerships with RMIT spin-off, Diagnostic Array Systems.
The company also announced the appointment of US-based consultant Richard O'Connor to its advisory board. Managing Director David Breeze said O'Connor's corporate experience and access to US networks was of the highest calibre.
Giving rotavirus vaccine at birth benefits gut bacteria
Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
